Lenalidomide for multiple myeloma: Cost-effectiveness in patients with one prior therapy in England and Wales

European Journal of Health Economics

Volumn 14, Issue 3, 2013, Pages 507-514

  Brown, Ruth E ^a   Stern, Sean ^a   Dhanasiri, Sujith ^b   Schey, Steve ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Celgene Ltd (UK and Ireland)   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Dexamethasone; Lenalidomide; Multiple myeloma; Patient access scheme

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ADULT; ANEMIA; ARTICLE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; ANALOGS AND DERIVATIVES; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; MORTALITY; NATIONAL HEALTH SERVICE; STATISTICAL MODEL; SURVIVAL;

ADULT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOLOGIC FACTORS; MALE; MODELS, ECONOMIC; MULTIPLE MYELOMA; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84880758321     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0395-6     Document Type: Article

References (25)

1. Cancer Research UK: Multiple myeloma - UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/incidence/ index.htm (2010). Accessed 19 July 2011
2. Scott, L.J.; Lyseng-Williamson, K.A.: Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 71, 625-649 (2011)
3. Schey, S.; Higginson, I.: Cost-effectiveness of lenalidomide in multiple myeloma. Expert Rev. Pharmacoecon. Outcomes Res. 10, 229-238 (2010)
4. Drayson, M.T.; Augustson, B.M.; Begum, G.; et al.: Survival from relapse and the influence of therapy (Abstract PO-665). Haematologica 92, 173 (2007)
5. Kumar, S.K.; Rajkumar, S.V.; Dispenzieri, A.; et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516-2520 (2008)
6. Stadtmauer, E.A.; Weber, D.M.; Niesvizky, R.; et al.: Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur. J. Haematol. 82, 426-432 (2009)
7. Dimopoulos, M.A.; Palumbo, A.; Attal, M.; et al.: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25, 749-760 (2011)
8. Caro, J.J.: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23, 323-332 (2005) (Pubitemid 40677051)
9. Dimopoulos, M.; Spencer, A.; Attal, M.; et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123-2132 (2007) (Pubitemid 350146107)
10. Weber, D.; Knight, R.; Chen, C. et al.: Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110, 412 (2007)
11. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf (June 2008). Accessed 19 July 2011
12. Durie, B.G.; Harousseau, J.L.; Miguel, J.S.; et al.: International uniform response criteria for multiple myeloma. Leukemia 20, 1467-1473 (2006) (Pubitemid 44264086)
13. Ishak, K.J.; Caro, J.J.; Drayson, M.T.; et al.: Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health 14, 672-678 (2011)
14. van Agthoven, M.; Segeren, C.M.; Buijt, I.; et al.: A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur. J. Cancer 40, 1159-1169 (2004) (Pubitemid 38526334)
15. Ossa, D.F.; Briggs, A.; McIntosh, E.; Cowell, W.; Littlewood, T.; Sculpher, M.: Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 25, 223-237 (2007) (Pubitemid 46376832)
16. Lloyd, A.; Nafees, B.; Narewska, J.; Dewilde, S.; Watkins, J.: Health state utilities for metastatic breast cancer. Br. J. Cancer 95, 683-690 (2006) (Pubitemid 44373482)
17. Cykert, S.; Joines, J.D.; Kissling, G.; Hansen, C.J.: Racial differences in patients' perceptions of debilitated health states. J. Gen. Intern. Med. 14, 217-222 (1999) (Pubitemid 29196423)
18. Coffey, J.T.; Brandle, M.; Zhou, H.; et al.: Valuing health-related quality of life in diabetes. Diabetes Care 25, 2238-2243 (2002) (Pubitemid 41071034)
19. Mathias, S.D.; Putterman, C.G.; Prebil, L.A.; et al.: A health-related quality of life measure in patients with deep vein thrombosis: a validation study. Drug Inf. J. 33, 1173-1187 (1999)
20. Department of Health: The 2009 pharmaceutical price regulation scheme. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-091825 (December 11, 2008). Accessed 19 July 2011
21. Department of Health: NHS reference costs 2008-2009. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-111591 (2010). Accessed 19 July 2011
22. Richardson, P.G.; Weller, E.; Lonial, S.; et al.: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679-686 (2010)
23. Richards, M.: Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-089927 (November 4, 2008). Accessed 19 July 2011
24. Steinbach, R.: Inequalities in the distribution of health and health care and its access, including inequalities relating to social class, gender, culture and ethnicity, and their causes. Equality, equity and policy: inequalities in the distribution of health and health care and its access. http://www.healthknowledge.org.uk/public-health-textbook/medical-sociology- policy-economics/4c-equality-equity-policy/inequalities-distribution (2009). Accessed 19 July 2011
25. Department of Health: Improving outcomes: a strategy for cancer. http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-123394.pdf (January 2011). Accessed 29 Feb 2012